Anti-HER2-Tra-hIgG4 (S228P)

Anti-HER2-Tra-hIgG4 (S228P) Unit size Cat. code Docs Qty Price
HER2 (trastuzumab) antibody - Human IgG4 (S228P)
100 µg

You may also need : Anti-β-Gal-hIgG4 (S228P) | View more associated products

Monoclonal human IgG4 (S228P) antibody against HER2

Anti-HER2-Tra-hIgG4 (S228P) features the constant region of the human IgG4 (S228P) isotype and the variable region of trastuzumab. Trastuzumab is a humanized IgG1 monoclonal antibody that targets the HER2 receptor (human epidermal growth factor receptor 2 also known as HER2/neu) that is found on the cell membrane of epithelial cells. HER2 plays an important role in normal cell growth and differentiation [1]. However, in certain types of cancers, particularly in breast and ovarian cancers, HER2 is over-expressed and causes uncontrollable cell proliferation. Binding of trastuzumab to HER2 results in cell death through different mechanisms including antibody-dependent cell-mediated cytotoxicity and phagocytosis [2, 3]. Trastuzumab has been approved by the FDA for the treatment of breast cancer.
Anti-HER2-Tra-hIgG4 (S228P) contains an engineered hinge region mutation (S228P) designed to prevent exchange of IgG4 molecules.
Anti-HER2-Tra-hIgG4 (S228P) was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.



1. Rubin I. & Yarden Y. 2001. The basic biology of HER2. Ann Oncol.12 Suppl 1:S3-8.
2. Collins DM. et al., 2012. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol. 23(7):1788-95.
3. Petricevic B. et al., 2013. Trastuzumab mediates antibody-dependent cell- mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med. 11:307.


Comparison of ADCC potency for native and engineered anti-HER2 antibody isotypes.
Comparison of ADCC potency for native and engineered anti-HER2 antibody isotypes.

Comparison of ADCC potency for native and engineered anti-HER2 antibody isotypes. Raji-HER2 cells were incubated with gradient concentrations of Anti-HER2-Tra mAbs, which feature the Trastuzumab variable region, or an Anti-β-galactosidase (β-Gal) mAb for 1 hour. Jurkat-Lucia™ NFAT-CD16 effector cells were then co-incubated with target cells for 6 hours. NFAT activation, reflecting the induced ADCC response, was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™. Percentages of the maximal response normalized to the IgG1 isotype are shown.

Back to the top


Specificity: Targets cells expressing HER2

Clonality: Monoclonal antibody

Isotype: Human IgG4 (S228P), kappa

Source: CHO cells

Purity: Purified by affinity chromatography with protein G

Quality control:

  • Binding of Anti-HER2-Tra-hIgG4 (S228P) to HER2 has been tested using flow cytometry.
  • The complete sequence of this antibody has been verified.
  • The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
Back to the top


anti-HER2-Tra-hIgG4 (S228P) antibody is provided azide-free and lyophilized.

  • 100 µg purified anti-HER2-Tra-hIgG4 (S228P) antibody

room temperature Product is shipped at room temperature

Back to the top


Customer Service
& Technical Support
Shopping cart is empty